Press

GenesisCare selects Dignitana and Aurora BioScience as preferred scalp cooling provider for its Australian medical oncology centres

GenesisCare selects Dignitana and Aurora BioScience as its preferred scalp cooling provider for its rapidly expanding Australia medical oncology centres

Dignitana has been selected as the preferred scalp cooling provider by Australia-headquartered GenesisCare, one of the largest networks of integrated oncology care in the world. This is Dignitana’s largest single commitment for DigniCap Delta units since the next generation device launched in 2019. The DigniCap® Scalp Cooling System minimizes hair loss from chemotherapy in patients with solid tumors.

The partnership will see the roll out of DigniCap Delta systems across GenesisCare’s seven pre-existing medical oncology facilities in Australia. DigniCap systems will then be installed over the next two to three years at additional  GenesisCare facilities in Australia as those locations begin to provide chemotherapy.

Over the past 12 months, GenesisCare has evaluated DigniCap Delta and  selected  Dignitana as the preferred provider based on:

  • Improved patient outcomes
  • Ease of use for clinical staff
  • Single patient wraps facilitating COVID-19 protocols

“We are delighted to be partnering with Aurora BioScience and Dignitana to offer this new scalp cooling technology to help patients save their hair throughout treatment,” said Ian Maytom, GenesisCare General Manager for Medical Oncology in Australia.

“Hair loss during chemotherapy can be extremely confronting for patients, many of whom are concerned about attracting attention and having to answer questions relating to their diagnosis and treatment.”

“At GenesisCare we believe in a holistic approach to cancer care which considers both the physical and emotional needs of our patients. We share Dignitana’s commitment to minimizing the emotional burdens associated with chemotherapy and supporting the psychological health of cancer patients.”

GenesisCare is a leading oncology provider globally, with more than 5,500 highly trained physicians, healthcare professionals and support staff delivering treatments to more than 400,000 people at 440 locations in Australia, the UK, the United States and Spain.

“With this partnership DigniCap is accessible to thousands more patients who would otherwise face the prospect of losing their hair during chemotherapy,” said William Cronin, Dignitana CEO. “GenesisCare truly is a global leader in oncology and we are thrilled to be working with their experienced and innovative team who share our commitment of putting patients first.”

Paving the way for wider adoption of scalp cooling in Australia, on September 20th Cancer Australia released updated Guidance for the management of early breast cancer patients  which now includes a recommendation to “Consider scalp cooling to reduce the risk of hair loss for patients receiving chemotherapy.” The Recommendation is similar to the 2019 National Comprehensive Cancer Network® (NCCN®) clinical practice guidelines for breast cancer which include scalp cooling as a Class 2A recommendation (version 1.2019).

“Demand for this important therapy is growing and together we will make scalp cooling a standard in modern cancer care,” said Darren Banks, Managing Director of Aurora BioScience, Dignitana’s longtime distribution partner and the exclusive importer and reseller of DigniCap in Australia and New Zealand. “There is no doubt that scalp cooling is now something that cancer patients want and need to improve their quality of life at a very difficult time.”

In 2019 the next generation DigniCap Delta device received clearance from the U.S. Food and Drug Administration and Australia’s Therapeutic Goods Administration. DigniCap is currently available in 40 countries worldwide.

For more information about the Delta Scalp Cooling system in Australia and New Zealand, please contact us on Australia (T) 1300 309 994 or New Zealand (T) 0800 533 272 or on info@aurorabioscience.com.au

 

MaxQ Thermal Shipping Technology

Aurora BioScience are pleased to announce that we have secured the Australia and New Zealand rights to supply the innovative MaxQ thermal shipping technology products. MaxQ develops and manufactures some of the most innovative Blood Bank and Hospital-optimised validated shipping and storage systems in the world.

MaxPlus coolers and specimen pouches are perfect for in-hospital use, stat transport, transfusion deliveries, haematology specimens pick-ups and more. The coolers are optimised for packed red cells, whole blood, platelets, plasma, specimens, vaccines, tissue and organs. All with no special handling or bench-time conditioning.

For more information please contact Aurora BioScience on 1300 309 994 or info@aurorabioscience.com.au

DigniCap Delta receives TGA approval

Dignitana receives TGA approval for DigniCap Delta scalp cooling system in Australia
First deliveries planned for October

Dignitana AB, world leader in scalp cooling innovation, today announced that the Therapeutic Goods Administration (TGA) has cleared DigniCap Delta® for use by health care providers in Australia. The new device is the fourth generation of The DigniCap® Scalp Cooling System and is indicated to prevent chemotherapy-induced hair loss in patients with solid tumors.

“DigniCap Delta changes everything about the way scalp cooling is done today,” said William Cronin, CEO of Dignitana. “The Delta system improves the clinical process, reduces nursing intervention and optimizes patient outcomes. This new device, developed along with our partner sites, allows them to accomplish all three of these objectives. We are thrilled to offer patients and clinicians this state-of-the-art advancement in cancer care. Australia is a very important market for us and, as scalp cooling has become a standard of care for patients here, the Delta device will enable our partner sites to offer this valuable therapy option to more patients and much more efficiently.”

DigniCap Delta uses solid state cooling for precise temperature control in an advanced and redesigned model of the 2015 TGA cleared DigniCap Scalp Cooling System. The new device delivers significant improvements over other scalp cooling systems on the market:
• Single patient use New cap system provides each patient with a flexible Cooling Wrap and an adjustable Thermal Cap designed to optimize scalp cooling outcomes and minimize clinic storage needs.
• Smaller size Streamlined profile is 54 percent smaller than the previous unit.
• Reduced nursing time Intuitive interface means up to 80 percent reduction in nursing time per patient infusion versus the existing device.

DigniCap Delta is now available to hospitals in Australia through Dignitana’s longtime distribution partner, Aurora BioScience, with first deliveries expected in October.

Darren Banks, Managing Director of Aurora BioScience, stated “We are pleased that this approval comes at a time when both awareness of and demand for scalp cooling are rapidly increasing. We are expecting significant interest in the Delta system moving forward as it is a major improvement over existing systems currently on the market.”

For More Information Contact Dignitana Investor Relations +1 469 518 5031 investorrelations@dignitana.com

For customer enquiries in Australia and New Zealand please contact Aurora BioScience on 1300 309 994 or info@aurorabioscience.com.au

About Dignitana AB (publ)
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1996 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Learn more at www.dignitana.se and www.dignicap.com. Erik Penser Bank AB, Certified Adviser, +46 (0) 8 463 83 00 certifiedadviser@penser.se www.penser.se

About Aurora BioScience Pty Ltd

Located in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets.

Since 2005, our mission has been to contribute to the enhancement of patient’s quality of life while assisting to improve clinical outcomes.

Our areas of interest include cancer therapies, haematology and blood products as well neurology/neurosurgery.

For more information please go to www.aurorabioscience.com.au

Venous Leg Ulcers (VLU) and dermaPACE – Australian Experience

SANUWAVE Takes Next Step in Wound Care Expansion

SANUWAVE Health, Inc.

DERMAPACE TECHNOLOGY SUGGESTS PROMISING OUTCOMES OF ACOUSTIC PRESSURE SHOCKWAVE TREATMENT FOR VENOUS LEG ULCERS (VLU)

GLOBAL VLU MARKET SIZE SIMILAR TO DFU

SUWANEE, GA –  (NewMediaWire) – March 08, 2018 – SANUWAVE Health, Inc. (OTCQB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, announces the publication of research that investigated the use of the dermaPACE® System in the treatment of Venous Leg Ulcers (VLU) in a case study series.  The study, titled “Treating venous leg ulcers with Extracorporeal Shockwave Technology (ESWT)” by Charne Miller (LaTrobe University), Suzanne Kapp (University of Melbourne), Jade Green (LaTrobe University), William McGuiness (LaTrobe Alfred Health Clinical School), and Michael Woodward (Austin Health/University of Melbourne), appeared in Wounds International 2017, Volume 8 Issue 3.  The case series was implemented at a medical professional lead, multidisciplinary outpatient wound clinic in Melbourne, Australia.

The case study series consisted of 6 patients, meeting eligibility criteria, presenting with venous leg ulcers (VLU) and who agreed to receive the dermaPACE treatment.  In order to better understand wound response to dose and energy, treatment selection used the two highest energy settings on the dermaPACE System, delivered at a frequency of 240 pulses/min. The shockwave pulse count was a function of wound area (cm2) with larger wounds requiring more shockwaves for treatment and thus longer time per therapy session than smaller wounds. The protocol used recommended one treatment delivered each week for 10 weeks.

Positive wound healing effects were observed for the majority of patients receiving ESWT.  At the conclusion of the case series the majority of wounds were either healed or healing was anticipated in a subsequent visit.

For the full release please go to:

http://www.newmediawire.com/news/sanuwave-takes-next-step-in-wound-care-expansion-4821231

 

Memorial Sloan Kettering orders 17 DigniCaps®

Dignitana AB, the world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was cleared in December 2015 by the U.S. FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, will be available at all Memorial Sloan Kettering Cancer Center (MSK) facilities that treat breast cancer.

The DigniCap® system is the first and only scalp-cooling device to receive FDA clearance. In the rigorous FDA clinical trial, seven out of ten patients with early-stage breast cancer kept at least 50% of their hair. The demand for the FDA-cleared DigniCap® system has been significant this year in the United States.

MSK, a world leader in cancer patient care, research, and educational programs, will now have the 17 units ordered in December of 2016 available for use by female patients undergoing breast cancer treatment in eight of their outpatient facilities in the New York Cityarea

 

http://www.prnewswire.com/news-releases/memorial-sloan-kettering-to-offer-dignicap-scalp-cooling-device-in-new-york-metro-area-locations-300405909.html

DigniCap for Breast Cancer patients in WA

Another update on the great success of our DigniCap Cooling System in Western Australia

Some comments:

“For the first 3 weeks after chemo & use of the DigniCap I didn’t experience any hair loss whatsoever. In fact, very surprisingly, my hair started to grow back! After 4 weeks of chemo, my hair was 8 millimetres long, & at the end of my chemo, 9 weeks later, my hair was 27 mm long!” – Belinda, 40, forensic scientist & avid cyclist, Perth

“Those entering our trial believe they will not only reap personal benefits, but will also be helping the next generaton of women undergoing chemotherapy” – – Prof Arlene Chan, Breast Medical Oncologists, Director Breast Clinical Trials Unit

For more information please go to

https://www.facebook.com/Ashley-and-Martin-Medical-Hair-Clinics-169747676432015/

BiaCare Compression Garments

SYDNEY, Australia. Aurora BioScience Pty. Ltd. today announced that it has entered into a sales and marketing distribution agreement for Australia and New Zealand with BiaCare, a leading provider of lymphoedema compression garments.

Aurora BioScience entered into a distribution agreement in December 2015; under the agreement Aurora Bioscience will be responsible for the sales, marketing, clinical support and distribution in both the Australian and New Zealand markets.

BiaCare is dedicated to helping meet the challenge of oedema with products that produce positive outcomes and improve the quality of life.

With well over 10 years of experience in manufacturing innovative compression garments, BiaCare is a diverse group of people, ranging from clinical professionals, engineers, marketing associates and design and production experts. All bring a unique set of talents to the table and share a common vision of providing the best therapeutic solutions available.

“The BiaCare range of compression garments are a truly innovative and important product line for the treatment of oedema, especially in the area of lymphoedema; these products have the potential to significantly improve the lives of patients” said Darren Banks, Managing Director of Aurora BioScience.

The BiaCare range includes compression garments for both lymphoedema and wound care, a full range of accessories as well as bandages, foams and other consumable items.

“We are extremely excited to be launching such an innovative and quality range in Australia and New Zealand and believe that the BiaCare products can have a significant impact on patient lives” stated Mr. Banks.

About Aurora BioScience Pty Ltd

Located in Sydney Australia, Aurora BioScience is committed to providing advanced, high quality medical devices and healthcare products to assist medical professionals within Australia, New Zealand and the Pacific Islands healthcare markets, to contribute to the enhancement of patient’s quality of life. Our areas of interest include lymphoedema, cancer therapies, neurology, pulmonology, and haematology and blood products.

For more information, please visit www.aurorabioscience.com.au

About BiaCare

The prefix “Bia” is of Greek origin and means “life”, similar to “Bio”. The name BiaCare captures, in a single word, the driving force of the company – to care about life. As we all know, life is full of physical challenges. BiaCare is dedicated to helping meet those challenges with products that produce positive outcomes, and improve the quality of life. BiaCare is located in Zeeland, Michigan, U.S.A.

www.biacare.com